Laboratory Medicine Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.
Department of Biochemistry, Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.
Biofactors. 2023 Jul-Aug;49(4):831-848. doi: 10.1002/biof.1947. Epub 2023 Mar 16.
This study investigated the chemotherapeutic effects of 5-fluorouracil (5-FU), metformin (Met), and/or thymoquinone (TQ) single/dual/triple therapies in the HT29, SW480 and SW620 colon cancer (CRC) cell lines. Cell cycle/apoptosis were measured by flow cytometry. The gene and protein expression of apoptosis (PCNA/survivin/BAX/Cytochrome-C/Caspase-3) and cell cycle (CCND1/CCND3/p21/p27) molecules, the PI3K/mTOR/HIF1α oncogenic pathway, and glycolysis regulatory enzymes were measured by quantitative-PCR and Western blot. Markers of oxidative stress were also measured by colorimetric assays. Although all treatments induced anti-cancer effects related to cell cycle arrest and apoptosis, the triple therapy showed the highest pro-apoptotic actions that coincided with the lowest expression of CCND1/CCND3/PCNA/survivin and the maximal increases in p21/p27/BAX/Cytochrome-C/Caspase-3 in all cell lines. The triple therapy also revealed the best suppression of the PI3K/mTOR/HIF1α pathway by increasing its endogenous inhibitors (PTEN/AMPKα) in all cell lines. Moreover, the lowest expression of lactate dehydrogenase and pyruvate dehydrogenase kinase-1 with the highest expression of pyruvate dehydrogenase were seen with the triple therapy, which also showed the highest increases in oxidative stress markers (ROS/RNS/MDA/protein carbonyl groups) alongside the lowest antioxidant levels (GSH/CAT) in all cell lines. In conclusion, this is the first study to reveal enhanced anti-cancer effects for metformin/thymoquinone in CRC that were superior to all monotherapies and the other dual therapies. However, the triple therapy approach showed the best tumoricidal actions related to cell cycle arrest and apoptosis in all cell lines, possibly by enhancing oxidative glycolysis and augmenting oxidative stress through stronger modulation of the PI3K/mTOR/HIF1α oncogenic network.
这项研究调查了氟尿嘧啶(5-FU)、二甲双胍(Met)和/或百里醌(TQ)单/双/三联疗法在 HT29、SW480 和 SW620 结肠癌细胞系中的化疗效果。通过流式细胞术测量细胞周期/凋亡。通过定量 PCR 和 Western blot 测量凋亡(PCNA/survivin/BAX/Cytochrome-C/Caspase-3)和细胞周期(CCND1/CCND3/p21/p27)分子、PI3K/mTOR/HIF1α致癌通路以及糖酵解调节酶的基因和蛋白表达。还通过比色法测定氧化应激标志物。尽管所有治疗均诱导与细胞周期阻滞和细胞凋亡相关的抗癌作用,但三联疗法显示出最强的促凋亡作用,与所有细胞系中 CCND1/CCND3/PCNA/survivin 的表达最低以及 p21/p27/BAX/Cytochrome-C/Caspase-3 的最大增加一致。三联疗法还通过增加所有细胞系中其内源性抑制剂(PTEN/AMPKα)来显示对 PI3K/mTOR/HIF1α 通路的最佳抑制作用。此外,与所有细胞系中的乳酸脱氢酶和丙酮酸脱氢酶激酶-1 表达最低和丙酮酸脱氢酶表达最高相对应,三联疗法也显示出氧化应激标志物(ROS/RNS/MDA/protein carbonyl groups)的最高增加以及所有细胞系中抗氧化剂水平(GSH/CAT)的最低水平。总之,这是第一项研究,揭示了二甲双胍/百里醌在 CRC 中的抗癌作用增强,优于所有单药治疗和其他双药治疗。然而,三联疗法在所有细胞系中显示出最强的抗肿瘤作用,与细胞周期阻滞和凋亡有关,这可能是通过增强氧化糖酵解以及通过更强的 PI3K/mTOR/HIF1α 致癌网络调节来增强氧化应激来实现的。